Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PTGX – Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc.
PTGX
$85.08
Name : Protagonist Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,318,519,808.00
EPSttm : 0.66
finviz dynamic chart for PTGX
Protagonist Therapeutics, Inc.
$85.08
0.55%
$0.465

Float Short %

9.25

Margin Of Safety %

-32

Put/Call OI Ratio

0.32

EPS Next Q Diff

0.16

EPS Last/This Y

-6.34

EPS This/Next Y

2.19

Price

84.61

Target Price

89.86

Analyst Recom

1.21

Performance Q

50.52

Relative Volume

0.58

Beta

2.18

Ticker: PTGX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20PTGX76.720.310.4215164
2025-10-21PTGX74.960.310.5415450
2025-10-22PTGX73.50.310.1315734
2025-10-23PTGX74.060.311.7915940
2025-10-24PTGX74.880.380.0917551
2025-10-27PTGX75.140.380.5617554
2025-10-28PTGX78.630.370.1417604
2025-10-29PTGX76.670.370.4217784
2025-10-30PTGX77.860.360.3617795
2025-10-31PTGX78.690.370.7617842
2025-11-03PTGX75.90.371.0117898
2025-11-04PTGX76.680.371.4417977
2025-11-05PTGX77.830.380.0518068
2025-11-06PTGX79.830.370.4618165
2025-11-07PTGX79.60.370.1318264
2025-11-10PTGX83.260.370.0418592
2025-11-11PTGX85.560.320.0320686
2025-11-12PTGX84.860.320.1120803
2025-11-13PTGX83.310.320.2920806
2025-11-14PTGX84.690.320.0720953
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20PTGX76.72-17.3- -2.02
2025-10-21PTGX74.96-19.2- -2.04
2025-10-22PTGX73.50-19.2- -2.04
2025-10-23PTGX73.97-19.2- -2.04
2025-10-24PTGX74.83-19.2- -2.04
2025-10-27PTGX75.15-19.2- -2.04
2025-10-28PTGX78.51-19.2- -2.04
2025-10-29PTGX76.64-19.2- -2.04
2025-10-30PTGX77.85-19.2- -2.04
2025-10-31PTGX78.62-19.2- -2.04
2025-11-03PTGX75.91-19.2- -2.04
2025-11-04PTGX76.68-19.2- -2.04
2025-11-05PTGX77.85-19.2- -2.04
2025-11-06PTGX79.80-19.2- -2.04
2025-11-07PTGX79.54-19.2- -2.04
2025-11-10PTGX83.23-19.2- -2.04
2025-11-11PTGX85.56-129.0- -1.80
2025-11-12PTGX84.82-129.0- -1.88
2025-11-13PTGX83.19-129.0- -1.88
2025-11-14PTGX84.61-128.3- -1.87
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20PTGX-2.938.4511.31
2025-10-21PTGX-2.938.4511.31
2025-10-22PTGX-2.938.4511.31
2025-10-23PTGX-2.938.4511.31
2025-10-24PTGX-2.888.4511.30
2025-10-27PTGX-2.917.2310.74
2025-10-28PTGX-2.917.2310.74
2025-10-29PTGX-2.917.2310.74
2025-10-30PTGX-2.917.2310.74
2025-10-31PTGX-2.917.2310.74
2025-11-03PTGX-2.917.0410.74
2025-11-04PTGX-2.917.0410.74
2025-11-05PTGX-2.917.0410.74
2025-11-06PTGX-2.917.0410.74
2025-11-07PTGX-2.917.0410.74
2025-11-10PTGX-2.906.5910.69
2025-11-11PTGX-2.906.5910.69
2025-11-12PTGX-2.906.599.25
2025-11-13PTGX-2.906.599.25
2025-11-14PTGX-2.906.599.25
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.62

Avg. EPS Est. Current Quarter

-0.56

Avg. EPS Est. Next Quarter

-0.46

Insider Transactions

-2.9

Institutional Transactions

6.59

Beta

2.18

Average Sales Estimate Current Quarter

31

Average Sales Estimate Next Quarter

51

Fair Value

57.49

Quality Score

54

Growth Score

59

Sentiment Score

97

Actual DrawDown %

9.3

Max Drawdown 5-Year %

-85.8

Target Price

89.86

P/E

133.58

Forward P/E

110.46

PEG

P/S

25.28

P/B

8.19

P/Free Cash Flow

83.02

EPS

0.63

Average EPS Est. Cur. Y​

-1.87

EPS Next Y. (Est.)

0.32

Target Price Estimates Raised

3

Target Price Estimates Lowered

Profit Margin

21.94

Relative Volume

0.58

Return on Equity vs Sector %

-19.8

Return on Equity vs Industry %

-5

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.11

EBIT Estimation

Protagonist Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 128
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading